| Liver arginase | |||||||
|---|---|---|---|---|---|---|---|
 | |||||||
| Identifiers | |||||||
| Symbol | ARG1 | ||||||
| NCBI gene | 383 | ||||||
| HGNC | 663 | ||||||
| OMIM | 608313 | ||||||
| RefSeq | NM_000045 | ||||||
| UniProt | P05089 | ||||||
| Other data | |||||||
| EC number | 3.5.3.1 | ||||||
| Locus | Chr. 6q23 | ||||||
| |||||||
| Arginase, type II | |||||||
|---|---|---|---|---|---|---|---|
| Identifiers | |||||||
| Symbol | ARG2 | ||||||
| NCBI gene | 384 | ||||||
| HGNC | 664 | ||||||
| OMIM | 107830 | ||||||
| RefSeq | NM_001172 | ||||||
| UniProt | P78540 | ||||||
| Other data | |||||||
| EC number | 3.5.3.1 | ||||||
| Locus | Chr. 14q24.1 | ||||||
| |||||||
Arginase (EC3.5.3.1,arginine amidinase,canavanase,L-arginase,arginine transamidinase) is amanganese-containingenzyme. The reaction catalyzed by this enzyme is:
It is the finalenzyme of theurea cycle. It is ubiquitous to all domains of life.
Arginase belongs to theureohydrolase family of enzymes.
Arginase catalyzes the fifth and final cytosolic step in theurea cycle, a series of biochemical reactions in mammals during which the body disposes of harmfulammonia. Specifically, arginase converts L-arginine into L-ornithine and urea.[2] Mammalian arginase is active as a trimer, but some bacterial arginases are hexameric.[3] The enzyme requires a binuclear manganese cluster for optimal activity. A single hydroxide ion bridges these Mn2+ions, oriented to serve as anucleophile that attacks the guanidinium group of L-arginine, hydrolyzing it to form ornithine and urea.[4]
In most mammals, two isozymes of this enzyme exist; the first, Arginase I, functions in the urea cycle, and is located primarily in the cytoplasm of hepatocytes (liver cells). The second isozyme, Arginase II, has been implicated in the regulation of intracellular arginine/ornithine levels. It is located in mitochondria of several tissues in the body, with most abundance in the kidney and prostate. It may be found at lower levels in macrophages, lactating mammary glands, and brain.[5] The second isozyme may be found in the absence of other urea cycle enzymes.[4]
The first crystal structure of arginase was reported in 1996 by the research group ofDavid W. Christianson at theUniversity of Pennsylvania.[6] The mechanism advanced in this paper begins with the binding of L-arginine in the enzyme active site, held in place by hydrogen bonding between the guanidinium group and Glu227. This orients the guanidinium group for nucleophilic attack by the metal-bridging hydroxide ion to form a tetrahedral intermediate. The manganese ions stabilize the hydroxyl group in the tetrahedral intermediate, as well as the developing sp3 lone electron pair on the NH2 group as the tetrahedral intermediate is formed.[7]
Arginase exhibits very narrow specificity for substrate L-arginine.[8] Modifying the substrate structure and/or stereochemistry severely diminishes catalytic activity. This specificity results from the high number of hydrogen bonds between substrate and enzyme; direct or water-mediated hydrogen bonds saturate both the four acceptor positions on the alpha carboxylate group and all three donor positions on the alpha amino group.[9] N-hydroxy-L-arginine (NOHA), an intermediate of NO biosynthesis, is a moderate inhibitor of arginase. The crystal structure of its complex with the enzyme reveals that it displaces the metal-bridging hydroxide ion and bridges the binuclear manganese cluster.[8]
2(S)-Amino-6-boronohexonic acid (ABH)[10] is an L-arginine analogue that binds as a tetrahedral boronate anion, which mimics the tetrahedral intermediate formed in catalysis; ABH is a potent inhibitor of human arginase I.[9][11]
Arginase II is coexpressed withnitric oxide (NO) synthase in smooth muscle tissue, such as the muscle in the genitals of both men and women. The contraction and relaxation of these muscles is regulated by nitric oxide (NO) generated by NO synthase, which causes rapid relaxation of smooth muscle tissue and facilitates engorgement of tissue necessary for normal sexual response. However, since NO synthase and arginase compete for the same substrate (L-arginine), over-expressed arginase can affect NO synthase activity and NO-dependent smooth muscle relaxation by depleting the substrate pool of L-arginine that would otherwise be available to NO synthase. In contrast, inhibiting arginase with ABH or other boronic acid inhibitors will maintain normal cellular levels of arginine, thus allowing for normal muscle relaxation and sexual response.[12]
Arginase is a controlling factor in both male erectile function and female sexual arousal, and is therefore a potential target for treatment of sexual dysfunction in both sexes.[13] Additionally, supplementing the diet with additional L-arginine will decrease the amount of competition between arginase and NO synthase by providing extra substrate for each enzyme.[14] Arginase also regulates NO-dependent processes in the immune response.[15]
Arginase deficiency typically refers to decreased function of arginase I, the liver isoform of arginase. This deficiency is commonly referred to as hyperargininemia orarginemia. The disorder is hereditary andautosomal recessive. It is characterized by lowered activity of arginase inhepatic cells. It is considered to be the rarest of the heritable defects inureagenesis. Arginase deficiency, unlike other urea cycle disorders, does not entirely prevent ureagenesis. A proposed reason for the continuation of arginase function is suggested by increased activity of arginase II in the kidneys of subjects with arginase I deficiency. Researchers believe that buildup of arginine triggers increased expression of arginase II. The enzymes in the kidney will then catalyze ureagenesis, compensating somewhat for a decrease in arginase I activity in the liver. Due to this alternate method of removing excessarginine and ammonia from the bloodstream, subjects with arginase deficiency tend to have longer lifespans than those who have other urea cycle defects.[16]
Symptoms of thedisorder include neurological impairment,dementia, retardation of growth, and hyperammonemia. While some symptoms of the disease can be controlled via dietary restrictions andpharmaceutical developments, no cure or completely effective therapy currently exists.[16]
